Analyst action, March 13

IDEAYA Biosciences (NASDAQ:IDYA) initiated with Buy rating and $12 (192% upside) price target at Roth Capital.

Menlo Therapeutics (NASDAQ:MNLO) resumed with Overweight rating and $15 (466% upside) at Canto Fitzgerald.

Amarin (NASDAQ:AMRN) upgraded to Buy with a $28 (143% upside) price target at Goldman Sachs. Shares up 8% premarket.

CymaBay Therapeutics (NASDAQ:CBAY) upgraded to Outperform with a $4 (184% upside) price target at Oppenheimer. Upgraded to Overweight with a $5 price target at Cantor.

Denali Therapeutics (NASDAQ:DNLI) upgraded to Outperform at Evercore ISI.

Incyte (NASDAQ:INCY) upgraded to Buy with an $83 (22% upside) price target at Bank of America citing the potential of ruxolitinib cream for atopic dermatitis.

Ionis Pharmaceuticals (NASDAQ:IONS) upgraded to Outperform with a $70 (58% upside) pricer target at Evercore ISI.

Pieris Pharmaceuticals (NASDAQ:PIRS) upgraded to Outperform with a $5 (211% upside) price target at Baird.

Inovio Pharmaceuticals (NASDAQ:INO) downgraded to Neutral with an $8 (16% downside risk) price target at Piper Sandler. Downgraded to Sector Perform with a $7 price target at RBC. Shares down 19% premarket.

Rubius Therapeutics (NASDAQ:RUBY) downgraded to Equal Weight at Morgan Stanley and Market Perform with a $4 (flat) price target at SVB Leerink.

Senseonics Holdings (NYSEMKT:SENS) downgraded to Neutral at BTIG Research and Neutral at Guggenheim.

ViewRay (NASDAQ:VRAY) downgraded to Neutral at BTIG.

Vir Biotechnology (NASDAQ:VIR) downgraded to Neutral with a $37 (2% downside risk) price target at Goldman. Shares down 4% premarket.

https://seekingalpha.com/news/3551475-goldman-sees-143-upside-in-amarin-in-premarket-analyst-action